Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ejhf.3415 | DOI Listing |
Publication Analysis
Top Keywords
reply 'empagliflozin
4
'empagliflozin glucagon-like
4
glucagon-like peptide-1
4
peptide-1 receptor
4
receptor agonists
4
agonists brothers
4
brothers heart
4
heart failure?'
4
reply
1
glucagon-like
1
Similar Publications
Reply to 'Empagliflozin and glucagon-like peptide-1 receptor agonists: The brothers for heart failure?'.
Eur J Heart Fail
October 2024
University of Groningen, Groningen, The Netherlands.
Reply: Aspirin and GLP-1RAs-The missing confounders of empagliflozin for MASLD without diabetes mellitus?
Hepatology
January 2025
Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong.
Author's reply to the letter to the editor: "Effects of dapagliflozin and empagliflozin on 6‑min walk distance in heart failure with preserved and reduced ejection fraction: A systematic review and meta‑analysis of randomized controlled trials involving 2624 patients".
Eur J Clin Pharmacol
November 2024
Department of Physical Pharmacy and Pharmacokinetics, Faculty of Pharmacy, Poznań University of Medical Sciences, Rokietnicka 3 St., 60-806, Poznań, Poland.
Empagliflozin in Patients with Chronic Kidney Disease. Reply.
N Engl J Med
June 2023
University of Oxford, Oxford, United Kingdom
Authors' reply to the letter to the editor regarding "Effect of empagliflozin on plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with type 2 diabetes".
Diabetes Res Clin Pract
September 2022
Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy. Electronic address:
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!